Jump to content

ArtDeCo Study


meistersinger
 Share

Recommended Posts

http://clinicaltrials.gov/ct2/show/related/NCT01457677

 

This refers to the Art DeCo study being done by Hoffman LaRoche. Anyone have further details?

History:

1995--Prozac--Quit CT by GP

1995--Effexor--Quit per my GP

1996--Amitriphene--Quit CT when changed GP

2005--Citalopram and BusPar. Prescribed when I decompensated in my GP's office. GP referred me to behavior health. Psychiatrist prescibed these drugs. Taken off citalopram in 2011 due to FDA warning. Quit Buspar during transition to viibryd.

Viibryd--2011 to present. Had a severe reaction in March 2012. Advised both GP and Psychiatrist I was trying to get off these drugs.

Link to comment
Share on other sites

  • Administrator

Moved from Journals. In the Journals section, please follow the Journals posting format. Thanks.

 

It will take several years before results from this study are available. Generally, it's not worth speculating whether a study in the recruiting stage has any significance, unless you want to be in the study.

This is not medical advice. Discuss any decisions about your medical care with a knowledgeable medical practitioner.

"It has become appallingly obvious that our technology has surpassed our humanity." -- Albert Einstein

All postings © copyrighted.

Link to comment
Share on other sites

  • 7 months later...
  • Administrator

Coincidentally, here’s a pharmaceutical company (Hoffmann-La Roche) recruiting people from the Web (I saw the link on Facebook) for what looks like an antidepressant add-on trial http://www.artdecostudy.com/what-to-expect.htm at a bunch of research centers.

 

This is how far study design has fallen. Might as well recruit people passing by on the street. Will everyone alleging to have major depression be found to have major depression? Hell, yes.

 

(Ironically, the ad resembles the bogus one for the new Soderburgh film Side Effects http://www.tryablixa.com/evaluation/ )

 

The study is the ARTDeCo study registered at http://www.clinicaltrials.gov/ct2/show/NCT01457677 Drug is RO4995819, to be taken for 6 weeks.

 

RO4995819 is an mGluR2/3 antagonist, see http://www.psychiatrictimes.com/mdd/content/article/10168/2090154 The goldmining operation moves to the glutamatergic neurotransmitter system.

This is not medical advice. Discuss any decisions about your medical care with a knowledgeable medical practitioner.

"It has become appallingly obvious that our technology has surpassed our humanity." -- Albert Einstein

All postings © copyrighted.

Link to comment
Share on other sites

 Share

×
×
  • Create New...

Important Information

Terms of Use Privacy Policy